GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

NCT01420861 | Terminated Phase 2 Results

• 1 other identifier: G200707
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 7

Brief Summary

The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response and Serum PSA progression)

Conditions

Prostate Cancer

Keywords

castrate resistant

Outcome Measures

Primary Outcomes (1)

• Decline in Serum PSA

  30 days

Study Arms (1)

1000 mg GTx-758 BID

EXPERIMENTAL

subjects will receive daily doses of 1000 mg GTx-758

Drug: GTx-758

Interventions

GTx-758 DRUG

two GTx 758 tablets per day

1000 mg GTx-758 BID

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be over 18 years of age
• Be able to communicate effectively with the study personnel
• Have histologically confirmed prostate cancer
• ECOG performance status of 0 to 2
• Have been treated with ADT(chemical or surgical) for at least 6 months
• Have castrate level of serum total testosterone (\<50 ng/dL)
• Have a history of serum PSA response after initiation of ADT, serum PSA response is at least a 90% reduction in serum PSA to \<10 ng/mL OR undetectable level of serum PSA (less tan or =0.2 ng/mL)
• Have rising serum PSA on two successive assessments at least 2 weeks apart and serum PSA levels ≥ 2 ng/mL or 2ng/mL and a 25% increase over the nadir after the initiation of ADT
• Be continued on androgen deprivation therapy throughout this study
• Give written informed consent prior to any study specific procedures
• Subjects must agree to use acceptable methods of contraception:
• oIf their female partners are pregnant or lactating acceptable methods of contraception from the time of the first administration of study medication until 3 months following administration of the last dose of study medication must be used. Acceptable methods are: Condom used with spermicidal foam/gel/film/cream/suppository. If the subject has undergone surgical sterilization (vasectomy with documentation of azospermia) a condom with spermicidal foam/gel/film/cream/suppository should be used. oIf the male subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 3 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository \[i.e. barrier method of contraception\], surgical sterilization (vasectomy with documentation of azospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}. oIf the female partner has undergone documented tubal ligation (female sterilization), a barrier method {condom used with spermicidal foam/gel/film/cream/suppository} should also be used. oIf the female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS) and a barrier method {condom with spermicidal foam/gel/film/cream/suppository} should also be used.

You may not qualify if:

• Known hypersensitivity or allergy to estrogen or estrogen like drugs;
• Have symptomatic metastatic prostate cancer
• Any disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk;
• History of abnormal blood clotting, Factor V Leiden clotting disorder, thrombotic disease (venous or arterial thrombotic events such as history of stroke, deep vein thrombosis (DVT), and/or pulmonary embolus (PE))
• Symptomatic congestive heart failure (NYHA Class III - IV), unstable angina pectoris, cardiac arrhythmia
• The presence of consistently abnormal laboratory values which are considered clinically significant. In addition, no subject with liver enzymes (ALT or AST) above 2 times the ULN, total bilirubin above 2 times the ULN, or serum creatinine above 1.5 ULN will be admitted to the study
• Received an investigational drug within a period of 90 days prior to enrollment in the study
• Received the study medication previously
• Currently taking testosterone, testosterone-like agents, or antiandrogens,including 5-alpha reductase inhibitors (may be eligible if allow a 6 week washout period after stopping antiandrogens);
• History of prior treatment of cancer chemotherapy agent (other than hormone therapy) or radiopharmaceutical for prostate cancer.
• Have taken ketoconazole within the previous 12 months prior to randomization into this study
• Have taken diethylstilbestrol or other estrogen products, ketoconazole, or abiraterone within the previous 12 months prior to randomization into this study
• Have taken body building or fertility supplements within 4 weeks of admission into the study
• Have been previously diagnosed with cancer (other than prostate cancer, superficial bladder cancer, or non-melanoma skin cancer).

Sponsors & Collaborators

• GTx: lead

Study Sites (7)

GTx Investigative Site

San Bernardino, California, 92404, United States

Location

GTx Investigational Site

Jeffersonville, Indiana, 47130, United States

Location

GTx Investigative Site

Albuquerque, New Mexico, 87109, United States

Location

GTx Investigative Site

Syracuse, New York, 13210, United States

Location

GTx Investigative Site

Bala-Cynwyd, Pennsylvania, 19004, United States

Location

GTx Investigative Site

San Antonio, Texas, 78229, United States

Location

GTx Investigative Site

Virginia Beach, Virginia, 23462, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

3-fluoro-N-(4-fluorophenyl)-4-hydroxy-N-(4-hydroxyphenyl)benzamide

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Results Point of Contact

• Title: Mary Breitmeyer
• Organization: Oncternal Therapeutics

mbreitmeyer@oncternal.com

8582092082

Study Officials

• Mitchell Steiner, MD

  GTx

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: DOUBLE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 18, 2011
• First Posted: August 22, 2011
• Study Start: September 1, 2011
• Primary Completion: December 1, 2012
• Study Completion: December 1, 2012
• Last Updated: October 6, 2023
• Results First Posted: October 6, 2023

Record last verified: 2023-09

Locations

US (7)